5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction - PubMed (original) (raw)
Review
5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction
Roger S Rittmaster. Best Pract Res Clin Endocrinol Metab. 2008 Apr.
Abstract
Androgens play an essential role in prostatic development and function, but are also involved in prostate disease pathogenesis. The primary prostatic androgen, dihydrotestosterone (DHT), is synthesized from testosterone by 5alpha-reductase types 1 and 2. Inhibition of the 5alpha-reductase isoenzymes therefore has potential therapeutic benefit in prostate disease. The two currently approved 5alpha-reductase inhibitors (5ARIs), finasteride and dutasteride, have demonstrated long-term efficacy and safety in the treatment of benign prostatic hyperplasia. Finasteride, a type-2 5ARI, has also been studied for its ability to reduce the incidence of biopsy-detectable prostate cancer in the Prostate Cancer Prevention Trial. Treatment with dutasteride, a dual 5ARI, has been shown to result in a greater degree and consistency of DHT suppression compared with finasteride. Two large-scale studies of dutasteride are currently investigating the role of near-maximal DHT suppression in the settings of prostate cancer risk reduction and expectant management of localized prostate cancer.
Similar articles
- A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
Montorsi F, Alcaraz A, Desgrandchamps F, Hammerer P, Schröder F, Castro R. Montorsi F, et al. Prostate. 2009 Jun 1;69(8):895-907. doi: 10.1002/pros.20939. Prostate. 2009. PMID: 19267353 Review. - The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
Musquera M, Fleshner NE, Finelli A, Zlotta AR. Musquera M, et al. Expert Rev Anticancer Ther. 2008 Jul;8(7):1073-9. doi: 10.1586/14737140.8.7.1073. Expert Rev Anticancer Ther. 2008. PMID: 18588452 Clinical Trial. - 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
Dörsam J, Altwein J. Dörsam J, et al. Prostate Cancer Prostatic Dis. 2009;12(2):130-6. doi: 10.1038/pcan.2008.56. Epub 2008 Nov 25. Prostate Cancer Prostatic Dis. 2009. PMID: 19030020 Review. - An overview on 5alpha-reductase inhibitors.
Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M. Aggarwal S, et al. Steroids. 2010 Feb;75(2):109-53. doi: 10.1016/j.steroids.2009.10.005. Epub 2009 Oct 30. Steroids. 2010. PMID: 19879888 Review. - Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
Marberger M. Marberger M. Nat Clin Pract Urol. 2006 Sep;3(9):495-503. doi: 10.1038/ncpuro0577. Nat Clin Pract Urol. 2006. PMID: 16964191 Review.
Cited by
- Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia.
Minutoli L, Rinaldi M, Marini H, Irrera N, Crea G, Lorenzini C, Puzzolo D, Valenti A, Pisani A, Adamo EB, Altavilla D, Squadrito F, Micali A. Minutoli L, et al. Int J Mol Sci. 2016 Aug 11;17(8):1311. doi: 10.3390/ijms17081311. Int J Mol Sci. 2016. PMID: 27529214 Free PMC article. Review. - Chronic administration of androgens with actions at estrogen receptor beta have anti-anxiety and cognitive-enhancing effects in male rats.
Osborne DM, Edinger K, Frye CA. Osborne DM, et al. Age (Dordr). 2009 Sep;31(3):191-8. doi: 10.1007/s11357-009-9114-3. Epub 2009 Aug 15. Age (Dordr). 2009. PMID: 19685169 Free PMC article. - Testosterone regulates tight junction proteins and influences prostatic autoimmune responses.
Meng J, Mostaghel EA, Vakar-Lopez F, Montgomery B, True L, Nelson PS. Meng J, et al. Horm Cancer. 2011 Jun;2(3):145-56. doi: 10.1007/s12672-010-0063-1. Horm Cancer. 2011. PMID: 21761342 Free PMC article. - Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer.
Knudsen KE, Penning TM. Knudsen KE, et al. Trends Endocrinol Metab. 2010 May;21(5):315-24. doi: 10.1016/j.tem.2010.01.002. Epub 2010 Feb 6. Trends Endocrinol Metab. 2010. PMID: 20138542 Free PMC article. Review. - The Effects of Aronia melanocarpa Extract on Testosterone-Induced Benign Prostatic Hyperplasia in Rats, and Quantitative Analysis of Major Constituents Depending on Extract Conditions.
Kim NH, Jegal J, Kim YN, Heo JD, Rho JR, Yang MH, Jeong EJ. Kim NH, et al. Nutrients. 2020 May 28;12(6):1575. doi: 10.3390/nu12061575. Nutrients. 2020. PMID: 32481550 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical